

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Laekna, Inc.

來凱醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2105)

VOLUNTARY ANNOUNCEMENT

UPDATES ON THE 24-WEEK MONOTHERAPY STUDY OF LAE102 SHOWED PROMISING WEIGHT LOSSES FAVORABLE CHANGES IN BODY COMPOSITION AND WELL TOLERATED SAFETY PROFILE

This announcement is made by Laekna, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board (the “**Board**”) of directors of the Company (the “**Directors**”) is pleased to provide an update that the Group has completed treatment in the low-dose cohorts of the 24-week monotherapy study of LAE102. Data from the completed low-dose cohorts were consistent with those from prior single-ascending-dose (SAD) and multiple-ascending-dose (MAD) studies of LAE102, showing favorable changes in body composition. Notably, the completed low-dose cohorts showed promising weight loss, alongside encouraging lean mass increases and fat mass reductions. Treatment over the 24-week period was well tolerated, with no serious adverse events reported and no reports of diarrhea, muscle spasms, or acne, consistent with the previously disclosed SAD and MAD studies.

The high-concentration formulation of LAE102 has recently become available, and the Group has completed subject enrollment in a high-dose cohort to further evaluate the efficacy and safety profile of LAE102 at high dose level over a 24-week treatment period.

Currently, the Group is actively seeking partners with global capabilities to accelerate the global development and commercialization of LAE102. The Group aims to bring this precision therapy to overweight and obese patients in need of novel treatment options to achieve quality weight management.

About LAE102

LAE102 is an internally discovered monoclonal antibody selectively targeting ActRIIA, a receptor that plays an important role in muscle regeneration and lipid metabolism. In the pre-clinical models, LAE102 has been shown to increase lean mass and decrease fat mass. In combination with a GLP-1 receptor agonist, LAE102 can further reduce fat mass and significantly regain the lean mass loss induced by GLP-1 receptor agonists. These findings position LAE102 as a promising drug candidate for achieving quality weight management.

RISK WARNING

LAE102 MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By Order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, October 13, 2026

As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.